Welcome to our dedicated page for Cambiar Aggressive Value ETF news (Ticker: CAMX), a resource for investors and traders seeking the latest updates and insights on Cambiar Aggressive Value ETF stock.
Camurus AB (CAMX) is frequently featured in news coverage related to long-acting biopharmaceutical therapies built on its proprietary FluidCrystal technology. Company announcements focus on clinical trial results, regulatory milestones, product approvals, and strategic collaborations across therapeutic areas such as opioid dependence, acromegaly, polycystic liver disease, obesity, and cardiometabolic health.
News about Camurus often highlights developments for its octreotide subcutaneous depot program, known as CAM2029 and marketed as Oczyesa in the EU and as Oclaiz in US regulatory filings. Coverage includes Phase 3 data from the ACROINNOVA studies in acromegaly, the POSITANO Phase 2b trial in polycystic liver disease, and regulatory steps such as European marketing authorization and FDA review of a resubmitted New Drug Application.
Another recurring theme in CAMX news is the company’s work in opioid dependence and opioid use disorder through its buprenorphine depot products Buvidal and Brixadi. Articles report on FDA approval of Brixadi in the US, clinical data comparing weekly and monthly depot injections to daily sublingual buprenorphine/naloxone, and analyses of effectiveness in individuals using fentanyl.
Investors and observers can also find updates on emerging programs such as CAM2056, a long-acting semaglutide depot for overweight and obesity, and on business agreements, including a collaboration and license deal with Eli Lilly for long-acting incretin products for cardiometabolic health. This news page aggregates these regulatory, clinical, and partnership developments so readers can follow how Camurus’ pipeline and approved products evolve over time.
Cambiar Investors announces the launch of the Cambiar Aggressive Value ETF (NYSE Arca: CAMX), transitioning from the Cambiar Aggressive Value Fund. This actively managed ETF focuses on a concentrated portfolio of 20-30 high-conviction stocks, aiming for strong absolute returns and referencing the Russell 1000 Value Index. Cambiar President Brian Barish highlights value investing's resurgence, correlating with the higher cost of capital and growth stock performance challenges. Investors may find CAMX appealing as market leadership shifts towards value.